New Crestor Death Reported
Death May Be Rare Side Effect Common to All Cholesterol-Lowering Statins
WebMD News Archive
Jan. 11, 2005 -- A patient taking the cholesterol-lowering drug Crestor has died, the drug's manufacturer reported Monday.
The death occurred in December 2004. Initial reports indicate the patient died of a muscle-damaging disease linked to Crestor and all other members of the family of cholesterol-lowering drugs known as statins. The same side disease, rhabdomyolysis, drove the cholesterol-lowering drug Baycol off the market.
Rhabdomyolysis is a condition in which muscle cells break down. This floods the blood with muscle proteins, sometimes leading to fatal kidney failure.
Neither Crestor nor any of its sister drugs, which include Lipitor, Pravachol, and Zocor, is as deadly as Baycol was. But some experts say Crestor is more dangerous than the rest of the family. The watchdog group Public Citizen has petitioned the FDA to ban Crestor. And Crestor was one of five FDA-approved drugs named in congressional testimony by maverick FDA researcher David Graham as being unsafe.
It's not clear whether the Crestor patient actually died of rhabdomyolysis, says AstraZeneca spokeswoman Emily Y. Denney. AstraZeneca makes Crestor and is a WebMD sponsor.
"We have received a report of a patient death," Denney tells WebMD. "The initial report listed rhabdomyolysis, but additional follow-up shows the clinical picture to be quite complex. The reported symptoms are more in line with malignant neuroleptic syndrome than with rhabdomyolysis."
Patients with malignant neuroleptic syndrome may have rhabdomyolysis along with a very high temperature and rigidity, but it isn't a common side effect of statin drugs. It's linked to the use of some psychiatric medications.
Despite the death, Denney says Crestor's safety profile is similar to that of other cholesterol-lowering drugs.
"Even if it does turn out to be a case of rhabdomyolysis, it is a very rare side effect with all statins -- less than one case in 10,000 patients," Denney says. "Approximately 10% of these 1-in-10,000 cases are reported as fatal for all statins. The documentation of one such death for Crestor must be understood in the context that there are more than 14 million Crestor prescriptions in over 4 million patients."